Brought to you by 
Tanabe Seiyaku licenses J&J development rights to SGLT inhibitor for diabetes
08 Jun 2015
Executive Summary
Tanabe Seiyaku Co. Ltd. licensed Johnson & Johnson R&D division RW Johnson Pharmaceutical Research Institute (RWJPRI) worldwide development and commercialization rights, except in Japan, Indonesia, China, and Taiwan, to its preclinical sodium-dependent glucose transporter protein (SGLT) inhibitor T1095 (to be called RWJ394718) for diabetes mellitus (Type II).
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tanabe Seiyaku licenses J&J development rights to SGLT inhibitor for diabetes
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice